ReviewEndocrinology and metabolism (Seoul, Korea)2018
Recent Topics in Fibrodysplasia Ossificans Progressiva.
Review in Endocrinology and metabolism (Seoul, Korea), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 36 citations in OpenAlex.
- First-In-Human Study to Assess the Pharmacokinetics and Safety of DS-6016a After Single Subcutaneous Injection in Healthy Japanese Adults.Clinical pharmacology in drug development · 2026Trial
- BRCC3 Regulation of ALK2 in Vascular Smooth Muscle Cells: Implication in Pulmonary Hypertension.Circulation · 2024Article
- How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans Progressiva.Biomolecules · 2024Review
- Fibrodysplasia Ossificans Progressiva Mimics Generalized Dystonia Disorder: A Case Report.Cureus · 2023Article
- A Novel De Novo Frameshift Pathogenic Variant in the FAM111B Resulting in Progressive Osseous Heteroplasia Phenotype.Calcified tissue international · 2023Article
- Cytoskeleton Reorganization in EndMT-The Role in Cancer and Fibrotic Diseases.International journal of molecular sciences · 2021Review
- Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2)/Activin A Receptor, Type 1 (ACVR1) as a Target for Human Disorders.Biomedicines · 2021Review
- New insights on fibrodysplasia ossificans progressiva: discussion of an autoptic case report and brief literature review.Intractable & rare diseases research · 2021Article
- Genomic Context and Mechanisms of theBiomedicines · 2021Review
- Screening for Small Molecule Inhibitors of BMP-Induced Osteoblastic Differentiation from Indonesian Marine Invertebrates.Marine drugs · 2020Article
- Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.Disease models & mechanisms · 2020Review
- Clinical Aspects and Current Therapeutic Approaches for FOP.Biomedicines · 2020Review
- A new diketopiperazine-like inhibitor of bone morphogenetic protein-induced osteoblastic differentiation produced by marine-derived Aspergillus sp. BFM-0085.The Journal of antibiotics · 2020Article
- Role of Signal Transduction Pathways and Transcription Factors in Cartilage and Joint Diseases.International journal of molecular sciences · 2020Review
- Alendronate disturbs femoral growth due to changes during immunolocalization of transforming growth factor-β1 and bone morphogenetic protein-2 in epiphyseal plate.World journal of experimental medicine · 2020Article
- Late-onset fibrodysplasia ossificans progressiva with atypical presentation: A case report.Case reports in women's health · 2019Article
- Propranolol and ascorbic acid in control of fibrodysplasia ossificans progressiva flare-ups due to accidental falls.Intractable & rare diseases research · 2019Article
- Discovery of Heterotopic Bone-Inducing Activity in Hard Tissues and the TGF-β Superfamily.International journal of molecular sciences · 2018Review
- Bone Morphogenetic Proteins.Cold Spring Harbor perspectives in biology · 2016Review
- Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.Molecular endocrinology (Baltimore, Md.) · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disease that is characterized by the formation of heterotopic bone tissues in soft tissues, such as skeletal muscle, ligament, and tendon. It is difficult to remove such heterotopic bones via internal medicine or invasive procedures. The identification of activin A receptor, type I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.